Melina Cioffi - 25 Apr 2025 Form 3 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
SVP Regulatory Affairs
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
25 Apr 2025
Net transactions value
$0
Form type
3
Filing time
07 May 2025, 09:10:34 UTC
Next filing
15 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cioffi Melina SVP Regulatory Affairs C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN /s/ Lori Braender, as Attorney-In-Fact 07 May 2025 0002066841

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AQST Common Stock 182,261 25 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AQST Employee Stock Option (right to buy) 25 Apr 2025 Common Stock 15,000 $7.86 Direct F2
holding AQST Employee Stock Option (right to buy) 25 Apr 2025 Common Stock 12,500 $6.62 Direct F3
holding AQST Employee Stock Option (right to buy) 25 Apr 2025 Common Stock 25,000 $4.07 Direct F4
holding AQST Employee Stock Option (right to buy) 25 Apr 2025 Common Stock 25,000 $0.8800 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 145,950 unvested Restricted Stock Units.
F2 The option became fully exercisable on August 31, 2023.
F3 The option became fully exercisable on November 24, 2023.
F4 The option became fully exercisable on June 10, 2024.
F5 The option became exercisable on August 5, 2023, and becomes exercisable as to the remaining 12,500 shares on August 5, 2025.